HomeCompareLLY vs NUE

LLY vs NUE: Dividend Comparison 2026

LLY yields 0.70% · NUE yields 1.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LLY wins by $1.50M in total portfolio value· pulled ahead in Year 3
10 years
LLY
LLY
● Live price
0.70%
Share price
$886.67
Annual div
$6.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.54M
Annual income
$1,207,534.19
Full LLY calculator →
NUE
NUE
● Live price
1.34%
Share price
$164.75
Annual div
$2.21
5Y div CAGR
36.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.0K
Annual income
$5,036.01
Full NUE calculator →

Portfolio growth — LLY vs NUE

📍 LLY pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLLYNUE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LLY + NUE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LLY pays
NUE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LLY
Annual income on $10K today (after 15% tax)
$59.72/yr
After 10yr DRIP, annual income (after tax)
$1,026,404.06/yr
NUE
Annual income on $10K today (after 15% tax)
$114.02/yr
After 10yr DRIP, annual income (after tax)
$4,280.61/yr
At 15% tax rate, LLY beats the other by $1,022,123.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LLY + NUE for your $10,000?

LLY: 50%NUE: 50%
100% NUE50/50100% LLY
Portfolio after 10yr
$787.3K
Annual income
$606,285.11/yr
Blended yield
77.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LLY right now

LLY
Analyst Ratings
33
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$1,243.95
+40.3% upside vs current
Range: $985.00 — $1,350.00
Altman Z
7.7
Piotroski
6/9
NUE
Analyst Ratings
18
Buy
11
Hold
3
Sell
Consensus: Buy
Price Target
$179.67
+9.1% upside vs current
Range: $176.00 — $183.00
Altman Z
4.4
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LLY buys
0
NUE buys
0
No recent congressional trades found for LLY or NUE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLLYNUE
Forward yield0.70%1.34%
Annual dividend / share$6.23$2.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%36.9%
Portfolio after 10y$1.54M$37.0K
Annual income after 10y$1,207,534.19$5,036.01
Total dividends collected$1.49M$15.0K
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusBuyBuy
Analyst price target$1,243.95$179.67

Year-by-year: LLY vs NUE ($10,000, DRIP)

YearLLY PortfolioLLY Income/yrNUE PortfolioNUE Income/yrGap
1$10,841$140.53$10,884$183.64$43.00NUE
2$11,884$284.74$11,901$255.72$17.00NUE
3← crossover$13,299$583.47$13,092$357.77+$207.00LLY
4$15,451$1,220.47$14,512$503.54+$939.00LLY
5$19,183$2,650.30$16,242$714.13+$2.9KLLY
6$26,676$6,150.32$18,402$1,022.61+$8.3KLLY
7$44,530$15,986.45$21,172$1,482.33+$23.4KLLY
8$97,527$49,880.25$24,836$2,182.08+$72.7KLLY
9$308,551$204,197.51$29,850$3,275.00+$278.7KLLY
10$1,537,684$1,207,534.19$36,975$5,036.01+$1.50MLLY

LLY vs NUE: Complete Analysis 2026

LLYHealthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Full LLY Calculator →

NUEMaterials

Nucor Corporation manufactures and sells steel and steel products. The company's Steel Mills segment produces hot-rolled, cold-rolled, and galvanized sheet steel products; plate steel products; wide-flange beams, beam blanks, and H-piling and sheet piling products; and bar steel products, such as blooms, billets, concrete reinforcing and merchant bars, and special bar quality products. It also engages in the steel trading and rebar distribution businesses. This segment sells its products to steel service centers, fabricators, and manufacturers in the United States, Canada, and Mexico. Its Steel Products segment offers hollow structural section steel tubing products, electrical conduits, steel racking, steel joists and joist girders, steel decks, fabricated concrete reinforcing steel products, cold finished steel products, steel fasteners, metal building systems, insulated metal panels, steel grating and expanded metal products, and wire and wire mesh products primarily for use in nonresidential construction applications. This segment also engages in the piling distribution business. The company's Raw Materials segment produces direct reduced iron (DRI); brokers ferrous and nonferrous metals, pig iron, hot briquetted iron, and DRI; supplies ferro-alloys; and processes ferrous and nonferrous scrap metal, as well as engages in the natural gas drilling operations. This segment sells its ferrous scrap to electric arc furnace steel mills and foundries for manufacturing process; and nonferrous scrap metal to aluminum can producers, secondary aluminum smelters, steel mills and other processors, and consumers of various nonferrous metals. It serves agriculture, automotive, construction, energy and transmission, oil and gas, heavy equipment, infrastructure, and transportation industries through its in-house sales force; and internal distribution and trading companies. Nucor Corporation was incorporated in 1958 and is based in Charlotte, North Carolina.

Full NUE Calculator →
📬

Get this LLY vs NUE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LLY vs SCHDLLY vs JEPILLY vs OLLY vs KOLLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.